skb315
mAbexperimentalADC
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2022 (NCT05367635)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Claudin-18BINDING AGENT
CLDN18 binding agent
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06242691 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2024 | Merck |
| NCT05367635 | Phase 1 | Mar 16, 2022 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Tianjin Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 1 | 1 | 2024 |
| Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1